CORRESPONDENCE

Anesthesiology
64:291, 1986

Improper Diagnostic Test May Account for High Incidence of Malignant Hyperthermia Associated with Masseter Spasm

To the Editor:—We were surprised when we read the paper entitled “Masseter spasm with anesthesia: incidence and implications,” by Schwartz et al.,¹ to realize that all 15 of their masseter spasm patients proved to be susceptible to malignant hyperpyrexia (MHS). In our experience of 100 patients presenting with muscle spasm following succinylcholine (almost invariably involving the masseters), 64 were found to be MHS and 36 to be normal (MHN) on in vitro testing. A similar proportion of MHS to MHN was reported by Rosenberg and co-workers.²

This leads us to question how Schwartz and associates diagnosed the MH status of their patients. The last sentence in the Methods section indicates that the MH phenotypes were determined by a method described by Allen and co-workers in 1980.³ Yet to our knowledge this method has not been evaluated independently against the now accepted muscle contracture tests performed on living muscle from known fulminant MH probands. The only description we have is in the form of an abstract describing a pilot study.⁴ Even in the abstract by Allen et al.,⁵ from which Schwartz et al.¹ derived their normal range, the SR Ca²⁺ uptake range of the MHS muscle overlaps with that of their non-MHS controls. If inappropriate muscle spasm is taken to indicate clinical MH, they could be subjecting themselves to a circular argument.

Our criticisms are strengthened when the incidence implications of their findings are considered. In their series of 15 patients, masseteric spasm correlated perfectly with MH. Thus, their incidence of MH is 1:800—the highest incidence ever quoted by a factor of about 10. Yet, in none of these cases was the outcome fatal—the lowest incidence ever quoted. As their study was retrospective, had MH occurred so commonly, serious complications would surely have been encountered.

Over the last 2 yr, there has been an increasing conformity in the laboratory criteria for the interpretation of the halothane and the caffeine contracture tests, especially among European centers (European Malignant Hyperpyrexia Group).⁶ With standardization of this type, true comparisons can be made between centers. It is unfortunate that the Boston group remains fiercely independent of this welcome trend.

F. R. ELLIS, Ph.D., M.B., Ch.B., F.F.A.R.C.S.
P. J. HALSALL, M.B., Ch.B.
Malignant Hyperpyrexia Investigation Unit
Department of Anaesthesia
University of Leeds
St. James’s Hospital
Leeds, LS9 7YF United Kingdom

REFERENCES
(Accepted for publication August 7, 1983.)

Masseter Spasm and Malignant Hyperthermia Are Not the Same Thing

To the Editor:—In “Masseter Spasm with Anesthesia: Incidence and Complications,” Schwartz et al. retrospectively attempt to correlate the occurrence of masseter spasm with anesthetic agents, signs, symptoms, and laboratory evaluations known to be associated with malignant hyperthermia.¹ We take issue with their conclusions about masseter spasm and its relation to malignant hyperthermia.

The retrospective nature of this study is a serious flaw. Much information is lacking: only two patients were monitored with transcutaneous nerve stimulation, eliminating the certainty of neuromuscular blockade in 13 patients.

Anesthesiology
64:291–292, 1986